Gilead Sciences, Inc. vs United States Oil ETF — how do they compare? Gilead Sciences, Inc. trades at $136 (market cap $168.35B), while United States Oil ETF trades at $126.5. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while United States Oil ETF pays none, and United States Oil ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | USO | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | — |
52-Week High | $155.80 | $152.96 |
52-Week Low | $110.56 | $66.17 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
USO is trading at $126.49, up 0.45% with bullish technical momentum as moving averages signal strength. The stock faces mixed sentiment amid ongoing Middle East supply disruptions and OPEC demand forecast revisions. Recent headlines highlight volatility from Hormuz tensions and shifting oil market dynamics.
Outlook remains volatile with supply risks supporting prices but demand concerns creating headwinds. Key resistance at $128-$132 and support at $123-$119 will dictate near-term direction. Geopolitical developments and inventory data remain critical catalysts for oil-linked equities.
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →